BridgeBio Pharma 2024 JPMorgan Healthcare Conference

BridgeBio Pharma presented its late-stage biotech pipeline at the 2024 JPMorgan Healthcare Conference, focusing on acoramidis for transthyretin amyloidosis and multiple genetic disease programs including achondroplasia and LGMD2i. The company outlined its strategy to generate peak-year sales from lead candidates and build a next-generation integrated biotech serving 450+ million genetic disease patients worldwide.